You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

~ Buy the ILEVRO (nepafenac) Drug Profile, 2024 PDF Report in the Report Store ~

ILEVRO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ilevro, and what generic alternatives are available?

Ilevro is a drug marketed by Harrow Eye and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.

DrugPatentWatch® Generic Entry Outlook for Ilevro

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ILEVRO?
  • What are the global sales for ILEVRO?
  • What is Average Wholesale Price for ILEVRO?
Drug patent expirations by year for ILEVRO
Drug Prices for ILEVRO

See drug prices for ILEVRO

Drug Sales Revenue Trends for ILEVRO

See drug sales revenues for ILEVRO

Recent Clinical Trials for ILEVRO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vance Thompson Vision - MTPhase 4
MDbackline, LLCN/A
Alcon ResearchN/A

See all ILEVRO clinical trials

Pharmacology for ILEVRO
Paragraph IV (Patent) Challenges for ILEVRO
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ILEVRO Ophthalmic Suspension nepafenac 0.3% 203491 1 2015-12-21

US Patents and Regulatory Information for ILEVRO

ILEVRO is protected by three US patents.

Patents protecting ILEVRO

Ophthalmic compositions containing a synergistic combination of two polymers
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Carboxyvinyl polymer-containing nanoparticle suspensions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Carboxylvinyl polymer-containing nanoparticle suspensions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Harrow Eye ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Harrow Eye ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Harrow Eye ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ILEVRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Harrow Eye ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 ⤷  Sign Up ⤷  Sign Up
Harrow Eye ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 ⤷  Sign Up ⤷  Sign Up
Harrow Eye ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for ILEVRO

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novartis Europharm Limited Nevanac nepafenac EMEA/H/C/000818
Nevanac is indicated for:, , , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients., ,
Authorised no no no 2007-12-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ILEVRO

See the table below for patents covering ILEVRO around the world.

Country Patent Number Title Estimated Expiration
Japan 4673339 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 9533457 ⤷  Sign Up
European Patent Office 2361610 Compositions ophtalmologiques contenant une association synergique de deux polymères (Ophthalmic compositions containing a synergistic combination of two polymers) ⤷  Sign Up
Spain 2206965 ⤷  Sign Up
Portugal 2116227 ⤷  Sign Up
Spain 2684752 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ILEVRO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0999825 CA 2013 00055 Denmark ⤷  Sign Up PRODUCT NAME: NEPAFENAC (3 MG/ML), HERUNDER NEPAFENAC I KOMBINATION MED GLACTOMANNANPOLYMERER, ISAER 3 MG/ML NEPAFENAC I KOMBINATION MED GALACTOMANNANPOLYMERER, SAMT OFTALMISKE SAMMENSAETNINGER DERAF; REG. NO/DATE: EU1/07/433/002 20130503
0999825 122013000085 Germany ⤷  Sign Up PRODUCT NAME: NEPAFENAC (OPHTHALMISCHE SUSPENSION); REGISTRATION NO/DATE: EU 1/07/433/002 20130503
0999825 92301 Luxembourg ⤷  Sign Up PRODUCT NAME: NEPAFENAC-SUSPENSION OPHTALMIQUE
0716600 C00716600/01 Switzerland ⤷  Sign Up PRODUCT NAME: NEPAFENAC; REGISTRATION NUMBER/DATE: SWISSMEDIC 58745 24.09.2008
0999825 C300622 Netherlands ⤷  Sign Up PRODUCT NAME: NEPAFENAC; REGISTRATION NO/DATE: EU/1/07/433/002 20130503
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.